GNPX News and Press, Genprex Inc. From 11/19/21

GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes. REQORSA—the company's main pipeline molecule—is targeting the Non-Small-Cell Lung Cancer Market. GNPX's share price is currently trading at around $2 after a ...

Longeveron LGVN +101% after Rare Pediatric Disease Designation for candidate Mammoth Energy Services TUSK +29% on EV charging contract Gracell Biotechnologies GRCL +26% on FDA Orphan Drug tag for GC012F BioHiTech Global BHTG +19% on Q3 results UWM Holdi...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the company’s president and chief executive officer Rodney Varner will be showcasing the company’s novel ge...

Presentation to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies f...

This week continues putting a focus on small-cap stocks. In particular, we’ve seen many stocks under $5 – or penny stocks – flying high on significant buying momentum. What initially began with a move in “Trump stocks” thanks to Digital World Acquisition C...

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer a...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of ch...

Genprex (NASDAQ:GNPX) appoints Mark S. Berger to the newly-created position of Chief Medical Officer and Hemant Kumar to the newly-created position of Chief Manufacturing and Technology Officer. Drs. Berger and Kumar will report to Rodney Varner, Chief Executive Offic...

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clinical trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline Genprex,...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, will be a featured presenter in both the CEO Roadshow Webinar series and the Benzinga Healthcare Small Cap Conference.Genprex president and...